MAGEB2 Binding Constructs for Low-Level Tumor Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing diagnostic assays for cancer antigens like MAGEB2 are not sensitive and specific enough to reliably detect low-level expression on tumor cells, particularly when the antigen is not expressed on the cell surface.
Innovation Solution
Development of antigen binding constructs, such as antibodies, that specifically target intracellular MAGEB2 by binding to defined epitopes, allowing for sensitive and precise detection and quantification of MAGEB2 in tumor samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunological diagnostic assays are used to detect tumor antigens, then the assay can detect a variety of disease conditions, but the sensitivity and specificity are not sufficient to reliably detect low-level expression of tumor antigens
Solution Approach 1:
The patent develops novel antibodies with optimized binding parameters (affinity, specificity) that can detect low-level MAGEB2 expression. The antibodies are engineered to bind with high affinity to specific epitopes of MAGEB2, enabling reliable detection at low expression levels where conventional assays fail.
2Measurement precision
If molecular diagnostic assays are used, then the required specificity and sensitivity can be achieved, but the ability to confirm proper expression of tumor antigen within tumor tissue sample is limited
Solution Approach 1:
The patent creates antibodies that can be applied across multiple diagnostic modalities including immunohistochemistry, flow cytometry, and ELISA. These multi-functional antibodies enable both molecular detection (providing sensitivity) and tissue expression confirmation (providing reliability) within a unified diagnostic platform.
3Adaptability or versatility
If conventional antibodies are used to detect MAGEB2, then general binding can be achieved, but the specificity for low-level expression and intracellular detection is insufficient
Solution Approach 1:
The patent identifies and targets specific local epitopes on MAGEB2 that are uniquely present in tumor-expressed forms of the protein. By focusing on these localized epitopic regions rather than general MAGEB2 structures, the antibodies achieve high specificity for tumor-derived MAGEB2 while maintaining binding capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antigen binding constructs provide a sensitive and precise method for detecting MAGEB2 expression in tumors, aiding in early cancer detection, classification, and predicting therapeutic response.
Implementation Method 1
an isolated antigen binding construct that binds MAGEB2, wherein the binding construct binds to an epitope comprising a sequence selected from SEQ ID NOs: 2, 3, 4, 562, or 388-554
Data Source
AI summary
The present invention relates to binding constructs comprising a domain which binds to MAGEB2. Moreover, the invention provides polynucleotides encoding the binding constructs, a vector comprising said polynucleotides and a host cell transformed or transfected with said polynucleotides or vectors. Furthermore, the invention provides processes for producing the binding constructs, methods of treatment using the binding constructs, diagnostic uses of the binding constructs, and kits comprising the binding constructs.